Recap: Zogenix Q1 Earnings

Shares of Zogenix ZGNX moved higher in after-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share fell 85.19% year over year to ($1.00), which beat the estimate of ($1.02).

Revenue of $13,684,000 higher by 995.60% from the same period last year, which beat the estimate of $12,330,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Zogenix hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: May 06, 2021

Time: 04:30 PM

ET Webcast URL: http://public.viavid.com/player/index.php?id=144590

Recent Stock Performance

52-week high: $32.42

52-week low: $17.20

Price action over last quarter: down 14.66%

Company Profile

Zogenix Inc is engaged in developing and commercializing therapeutic solutions for people living with serious and life-threatening rare CNS disorders and medical conditions. Its product candidate includes ZX008, low-dose fenfluramine for the treatment of Dravet syndrome, LGS, and potentially other rare and catastrophic epilepsy disorders.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: EarningsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!